<DOC>
	<DOCNO>NCT00981409</DOCNO>
	<brief_summary>The primary objective evaluate efficacy ( measure rate recurrent symptomatic Venous Thromboembolism [ VTE ] ( i.e. , Pulmonary thromboembolism [ PE ] Deep Vein Thrombosis [ DVT ] ) ) safety GSK576428 initial treatment subject acute PE open-label design .</brief_summary>
	<brief_title>The Treatment Acute Pulmonary Thromboembolism ( PE ) GSK576428 ( Fondaparinux Sodium ) Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Subjects confirm diagnosis ( Multi detectorrow CT [ MDCT ] ) acute symptomatic PE hemodynamically stable ( i.e. , condition anticoagulant therapy alone indicate ) ( time onset longer 5 day , subject without symptomatic DVT eligible ) Age : &gt; =20 year Gender : No restriction Female subject must either nonchildbearing potential ( postmenopausal &gt; 1 year , hysterectomy , sterilization ) , childbearing potential , negative pregnancy test screening , agree use contraception throughout study period . Hospitalization status : Subjects able stay hospital least initial treatment period . Written inform consent subject him/herself his/her legally acceptable representative . Written inform consent subject 's legally acceptable representative must obtain subject incapable give consent . Shock hemodynamic instability* . * : Defined shock decrease blood pressure ( systolic blood pressure &lt; 90 mmHg &gt; =40 mmHg ) last least 15 minute represent hemodynamically unstable condition due newly emergent arrhythmia , dehydration sepsis . Right cardiac function failure detect echocardiography screening . Requirement surgical thrombectomy , catheter intervention thrombolytic therapy current PE . Subjects ( example , freefloating thrombus femoral vein ilium MDCT screening ) insertion inferior vena cava filter indicate subject inferior vena cava filter present . Prior entry study , therapeutic dosage anticoagulant 24 hour treat current episode . Active , clinically significant bleed Thrombocytopenia ( platelet count &lt; 10×10⁴/µL screening ) Concurrent condition bleed risk ( e.g. , ulcer gastrointestinal tract , diverticulitis gastrointestinal tract , colitis , acute bacterial endocarditis , severe hypertension* , severe diabetes ) bleeding tendency . * : systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg Severe hepatic disorder Known hypersensitivity heparin , lowmolecularweight heparin ( LMWH ) warfarin Previous history cerebral hemorrhage Brain , spinal , ophthalmological surgery within 3 month prior entry study Previous history Heparininduced thrombocytopenia Patients anticoagulant therapy contraindicate take anticoagulant therapy due coexistent condition ( e.g . prosthetic heart valve implant ) . Severe renal disorder ( serum creatinine &gt; 2.0 mg/dL [ 180 µmol/L ] screen ) well hydrate subject Documented hypersensitivity contrast medium Use contraindicate drug combine injection contrast medium [ e.g. , antihyperglycemic metformin hydrochloride ( Glycoran® , Melbin® ) ] Participation therapeutic drug study clinical study within 6 month prior entry study Previous participation study GSK576428 Drug alcohol abuse Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg Recent surgery within 3 day prior entry study Life expectancy &lt; 3 month Pregnant woman , nurse mother , woman may pregnant , woman contemplate pregnancy study period Others investigator subinvestigator considers eligible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fondaparinux sodium</keyword>
	<keyword>contrast-enhanced MDCT</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Pulmonary thromboembolism</keyword>
</DOC>